📊 IRMD Key Takeaways
Is IRMD a Good Investment? Thesis Analysis
IRMD demonstrates exceptional financial health with best-in-class profitability metrics (76.7% gross margin, 31.2% operating margin, 26.8% net margin) and fortress-like balance sheet (7.98x current ratio, zero debt). The company generates substantial free cash flow ($17.2M, 20.5% FCF margin) with strong returns on equity (23.8%) and assets (20.7%), indicating efficient capital deployment in a specialized medical device market.
Why Buy IRMD? Key Strengths
- Exceptional profitability margins (gross 76.7%, operating 31.2%, net 26.8%) well above medical device industry averages
- Pristine balance sheet with $51.2M cash, zero long-term debt, and 7.98x current ratio providing substantial financial flexibility
- Strong cash generation with $17.2M free cash flow and 20.5% FCF margin demonstrating quality earnings
- High return on capital (ROE 23.8%, ROA 20.7%) indicating efficient business model and competitive advantages
- Stable revenue base with positive EPS growth (+16.7% YoY) despite flat top-line growth
IRMD Investment Risks to Consider
- Stagnant revenue growth (0.0% YoY) suggests market saturation, competitive pressures, or execution challenges in core markets
- Flat net income growth (0.0% YoY) despite EPS growth indicates share buyback dependency rather than organic business expansion
- Elevated insider trading activity (12 Form 4 filings in 90 days) warrants monitoring for potential insider concerns or hedging activity
- Single product/market concentration risk typical of specialized medical device companies with limited diversification
Key Metrics to Watch
- Revenue growth acceleration and market expansion into new customer segments
- Gross margin sustainability as competitive dynamics and product mix potentially shift
- Free cash flow generation and capital allocation decisions (reinvestment, acquisitions, or returns to shareholders)
- Operating leverage realization as revenue grows with relatively fixed cost base
IRMD Financial Metrics
💡 AI Analyst Insight
The 20.5% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 7.98x current ratio provides a solid financial cushion.
IRMD Profitability Ratios
IRMD vs Healthcare Sector
How IRADIMED CORP compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IRMD Overvalued or Undervalued?
Based on fundamental analysis, IRADIMED CORP appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IRMD Balance Sheet & Liquidity
IRMD 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: IRADIMED CORP's revenue has grown significantly by 100% over the 5-year period, indicating strong business expansion. The most recent EPS of $1.50 reflects profitable operations.
IRMD Growth Metrics (YoY)
IRMD Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $18.3M | $4.1M | $0.40 |
| Q2 2025 | $17.9M | $4.1M | $0.38 |
| Q1 2025 | $17.6M | $4.1M | $0.32 |
| Q3 2024 | $16.5M | $3.4M | $0.40 |
| Q2 2024 | $16.1M | $3.4M | $0.33 |
| Q1 2024 | $15.5M | $3.4M | $0.27 |
| Q3 2023 | $13.4M | $2.5M | $0.27 |
| Q2 2023 | $12.7M | $2.5M | $0.26 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
IRMD Capital Allocation
IRMD SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for IRADIMED CORP (CIK: 0001325618)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 25, 2026 | 4 | xslF345X06/form4-03252026_040301.xml | View → |
| Mar 18, 2026 | 4 | xslF345X06/form4-03182026_060343.xml | View → |
| Mar 10, 2026 | 4 | xslF345X05/form4-03102026_040301.xml | View → |
| Mar 9, 2026 | 4 | xslF345X05/form4-03092026_040305.xml | View → |
| Mar 6, 2026 | 10-K | irmd-20251231x10k.htm | View → |
❓ Frequently Asked Questions about IRMD
What is the AI rating for IRMD?
IRADIMED CORP (IRMD) has an AI rating of STRONG BUY with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IRMD's key strengths?
Claude: Exceptional profitability margins (gross 76.7%, operating 31.2%, net 26.8%) well above medical device industry averages. Pristine balance sheet with $51.2M cash, zero long-term debt, and 7.98x current ratio providing substantial financial flexibility.
What are the risks of investing in IRMD?
Claude: Stagnant revenue growth (0.0% YoY) suggests market saturation, competitive pressures, or execution challenges in core markets. Flat net income growth (0.0% YoY) despite EPS growth indicates share buyback dependency rather than organic business expansion.
What is IRMD's revenue and growth?
IRADIMED CORP reported revenue of $83.8M.
Does IRMD pay dividends?
IRADIMED CORP pays dividends, with $15.0M distributed to shareholders in the trailing twelve months.
Where can I find IRMD SEC filings?
Official SEC filings for IRADIMED CORP (CIK: 0001325618) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IRMD's EPS?
IRADIMED CORP has a diluted EPS of $1.75.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IRMD a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, IRADIMED CORP has a STRONG BUY rating with 85% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is IRMD stock overvalued or undervalued?
Valuation metrics for IRMD: ROE of 23.8% (sector avg: 15%), net margin of 26.8% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy IRMD stock in 2026?
Our dual AI analysis gives IRADIMED CORP a combined STRONG BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is IRMD's free cash flow?
IRADIMED CORP's operating cash flow is $24.9M, with capital expenditures of $7.8M. FCF margin is 20.5%.
How does IRMD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 26.8% (avg: 12%), ROE 23.8% (avg: 15%), current ratio 7.98 (avg: 2).